These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 15569979)

  • 41. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
    Helleman J; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Klijn JG; Sleijfer S; Foekens JA; Berns EM
    Clin Cancer Res; 2008 Sep; 14(17):5555-64. PubMed ID: 18765548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
    Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
    Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
    Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
    Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S
    Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment.
    Søreide JA; Lea OA; Varhaug JE; Skarstein A; Kvinnsland S
    Eur J Surg Oncol; 1992 Apr; 18(2):112-8. PubMed ID: 1582503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
    Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
    Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
    Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.